Det vi støtter (kun på engelsk)

Funded projects
1,200+
Men's Health Partners
20
Countries
21
"We work closely with our global men's health partners to ensure collaboration, transparency and accountability for every project we fund. We monitor this through report cards which detail what we seek to achieve, key measures and the impact." - Owen Sharp, CEO
Prostate Cancer
"Together with the brightest minds in research, we aim to achieve significant breakthroughs in the hope of beating prostate cancer. Our disruptive funding approach identifies revolutionary ways to accelerate health outcomes by creating strong, global collaborative teams." Dr. Colleen Nelson, Global Scientific Chair.
Men's Health
"One Mo can help change the face of men’s health through the powerful conversations created globally during Movember. Men have the chance to confidently discuss men’s health with people around them, resulting in men taking action early, helping change and save lives." Paul Villanti, Executive Director, Programmes
Mental health and suicide prevention
“We’re alarmed by the increasing number of men who take their own lives around the world. We are working to ensure all men and boys look after their mental health and are comfortable to reach out to others for support when they’re struggling.” 
Craig Martin, Global Director - Mental Health & Suicide Prevention programs
Testicular Cancer
“Despite being the 2nd most common cancer in young men, testicular cancer is often a forgotten cancer due to early detection and treatment. Our projects look at underinvested areas such as improving access to healthcare services and treatment options for relapse” Paul Villanti, Executive Director, Programmes.

GAP2 The Advanced Prostate Cancer Imaging Initiative

Movember Funding to Date

AUD 1,035,499

What we seek to achieve

To improve imaging techniques for men with advanced prostate cancer. By better determining where prostate cancer has spread and what sort of cells make up this spread, treatments can be better tailored for an individual.

Country
Australia
Implemented by
The Movember Foundation
Project start date
January 2014
Project Status
In Progress

About the project

As part of the Movember Foundation's GAP program, the GAP2 project has brought together leading researchers from around the world to collaborate, share knowledge and together build this groundbreaking project.

The GAP2 Advanced Prostate Cancer Imaging Initiative is made up of 3 distinct sub-projects. Each of these 3 projects is investigating the use of a novel, radioactive PET imaging tracer to investigate the spread of cancer cells in men with advanced disease.  

The three tracers under investigation are called: 

  1. Fluorodihydrotestosterone (FDHT) - a project with contributions from American, British, Australian and Dutch research groups, 
  2. Choline - a project with contributions from Canadian, Australian and British research groups, and 
  3. Prostate Specific Membrane Antigen (PSMA) - a joint American and Canadian research project.
This project will ultimately impact men with advanced disease.  This includes men who have a rising PSA test after surgery to remove their prostate gland and also men who have widespread, castrate-resistant prostate cancer.  These men may have better outcomes if treatments can be more appropriately directed by new imaging tests.

This project has been governed by the Movember GAP2 Project Research Advisory Committee - a global team of highly regarded experts in the field that have guided and shaped the project with the project leaders.

>
Page 1 of 19